Skip to main content

Table 3 Incidence rate and severity of adverse events in maintenance therapy

From: Clinical efficacy and safety of maintenance therapy for advanced non-small cell lung cancer: a retrospective real-world study

Adverse events

Grade

Cases (incidence rate %)

Leukopenia

Grade 1–2

27 (38.03%)

Grade 3–4

19 (26.76%)

Neutropenia

Grade 1–2

23 (32.39%)

Grade 3–4

12 (16.90%)

Thrombocytopenia

Grade 1–2

17 (23.94%)

Grade 3–4

7 (9.86%)

Anemia

Grade 1–2

31 (43.66%)

Grade 3–4

12 (16.90%)

Nausea

Grade 1–2

20 (28.17%)

Grade 3–4

3 (4.23%)

Vomiting

Grade 1–2

18 (25.35%)

Grade 3–4

2 (2.82%)

Diarrhea

Grade 1–2

7 (9.86%)

Grade 3–4

2 (2.82%)

Neurotoxicity

Grade 1–2

4 (5.63%)

Grade 3–4

1 (1.41%)

Transaminase elevation

Grade 1–2

13 (18.31%)

Grade 3–4

2 (2.82%)

Renal toxicity

Grade 1–2

9 (12.67%)

Grade 3–4

3 (4.23%)

Weakness

Grade 1–2

33 (46.47%)

Grade 3–4

5 (7.04%)

Rash

Grade 1–2

9 (12.67%)

Grade 3–4

3 (4.23%)

Myalgia

Grade 1–2

3 (4.23%)

Arrhythmia

Grade 1–2

2 (2.82%)